Estimated Glomerular Filtration rate (eGFR): A Serum Creatinine-Based Test for the Detection of Chronic Kidney Disease and its Impact on Clinical Practice

 
 

Anjly Jain1, Dimitri P. Mikhailidis2, Devaki R. Nair1*

 
  DOI 10.5001/omj.2012.62  
 
 
 
1Department of Clinical Biochemistry, Royal Free Hampstead NHS Trust, Pond Street, London, NW3 2QG.
2Department of Clinical Biochemistry, Royal Free Hospital Campus, UCL Medical School, Pond Street, London NW3 2QG.

Received: 15 Apr 2012
Accepted: 22 Apr 2012

*Address correspondence and reprint request to: Devaki R, Nair, Department of Clinical Biochemistry, Royal Free Hampstead NHS Trust, Pond Street, London, NW3 2QG.
 Email: [email protected]
 
 
 
 

How to cite this article

Jain A, Mikhailidis DP, Nair DR. Estimated Glomerular Filtration rate (eGFR): A Serum Creatinine-Based Test for the Detection of Chronic Kidney Disease and its Impact on Clinical Practice. Oman Med J 2012 May; 27(3):260.

How to cite this URL

Jain A, Mikhailidis DP, Nair DR. Estimated Glomerular Filtration rate (eGFR): A Serum Creatinine-Based Test for the Detection of Chronic Kidney Disease and its Impact on Clinical Practice. Oman Med J 2012 May; 27(3):260. Available from http://www.omjournal.org/fultext_PDF.aspx?DetailsID=252&type=fultext

 
 
 
 

To the Editor,

We read with interest the comprehensive review entitled "Estimated Glomerular Filtration rate (eGFR): A Serum Creatinine-Based Test for the detection of Chronic Kidney Disease and its Impact on Clinical Practice".1

We agree that the prevalence of chronic kidney disease (CKD) is very high worldwide and that there is a need for a reliable eGFR equation for screening, diagnosis and management.1,2

A low eGFR is a predictor of vascular risk.3 South Asians have a greater risk for vascular disease and CKD.4 Therefore, it is essential to have an appropriate equation to calculate a valid eGFR for this ethnic group. We compared 6 different eGFR equations. Our preliminary analysis (unpublished results) shows that calculated mean values using the different equations ranged from 90 to 116 and 87 to 102 ml/min or ml/min/1.73 m2 in males and females, respectively. The prevalence of CKD using a cut off of <60 ml/min or ml/min/1.73 m2 varied from 0.4% (Mayo Quadratic and Apollo-Chennai equations) to 5.4% (creatinine clearance based upon estimated fat free body mass equation). Apart from the Apollo-Chennai formula which was derived from residents in India, all the other equations were based on predominantly Caucasian populations.

It is possible that specific eGFR equations also need to be developed for each population (e.g., Middle-East). Differences between eGFR equations may relate to variation in body composition. We have shown (unpublished results) a relationship between body composition with kidney function; Skeletal Muscle Mass (SMM) was a predictor of serum creatinine after adjusting for age and sex (r=0.52; p=0.0025). Age- and sex- adjusted SMM was negatively associated and adjusted Percent Body Fat was positively associated with 4vMDRD-derived eGFR (r= -0.44; p<0.001 and r=0.40; p=0.004, respectively).

Apart from predicting vascular risk and CKD progression, the eGFR may be useful in identifying patients who will have contrast induced nephropathy (CIN).5,6 This is an important issue because of the large number of patients undergoing procedures involving contrast administration.5,6 Therefore, as Mula-Abed et al. suggest, there is a need for reliable markers for kidney function.1
 
 

References

1. Mula-Abed WA, Al Rasadi K, Al-Riyami D. Estimated Glomerular Filtration Rate (eGFR): A Serum Creatinine-Based Test for the Detection of Chronic Kidney Disease and its Impact on Clinical Practice. Oman Med J 2012 Mar;27(2):108-113.

2. Nair DR, Mehta S, Mikhailidis DP. Assessing renal function - searching for the perfect marker continues! Arch Med Sci 2011 Aug;7(4):565-567.

3. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al; European Association for Cardiovascular Prevention & Rehabilitation; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011 Jul;32(14):1769-1818.

4. Rao N, Eastwood SV, Jain A, Shah M, Leurent B, Harvey D, et al. Cardiovascular risk assessment of South Asians in a religious setting: a feasibility study. Int J Clin Pract 2012 Mar;66(3):262-269.

5. Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, et al; REMEDIAL II Investigators. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation 2011 Sep;124(11):1260-1269.

6. Paraskevas KI, Giannoukas AD, Kotsikoris I, Mikhailidis DP. Contrast-induced nephropathy and the vascular patient. Angiology 2010 Nov;61(8):721-723.